Moleculin Biotech completes enrollment in Phase 1b/2 Annamycin trial

Moleculin Biotech completed enrollment in the Phase 2 portion of the company’s U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases. Based on the data demonstrated to date, Moleculin believes that the median progression free response of greater than 60%, despite the patients in this study having received multiple prior chemotherapy regimens, exceeds expectations. The company expects to provide further additional updates on this trial in Q4. Annamycin currently has Fast Track Status and Orphan Drug Designation from the FDA for the treatment of soft tissue sarcoma, in addition to Orphan Drug Designation for the treatment of relapsed or refractory acute myeloid leukemia.